October 26, 2017 / 5:02 PM / in 8 months

BRIEF-GenKyoTex cash & cash equivalents and liquid investments at 15.3 million euros as of Sept 30​

Oct 26 (Reuters) - Genkyotex Sa:

* ‍TWO PHASE 2 CLINICAL TRIALS IN FIBROTIC INDICATIONS PROGRESSING ON TRACK IN Q3​

* ‍FIRST PUBLICATION HIGHLIGHTING GKT831 IN ONCOLOGY MODELS IN Q3​

* ‍CASH & CASH EQUIVALENTS AND LIQUID INVESTMENTS OF EUR 15.3 MILLION AS OF SEPT 30​

* ‍PHASE 2 CLINICAL TRIAL OF GKT831 ON TRACK TO DELIVER INTERIM RESULTS IN H1 2018​

* ‍P PHASE 2 CLINICAL TRIAL OF GKT831 TO DELIVER FULL RESULTS IN H2 2018​

* ‍ SECOND PHASE 2 TRIAL WITH GKT831 ON TRACK TO ENROLL FIRST PATIENT BY END OF 2017​

* ‍ GKT831 TRIAL WILL INCLUDE 142 PATIENTS​

* ‍CO EXPECTS TO RECEIVE A RESEARCH TAX CREDIT (CRÉDIT IMPÔT RECHERCHE) FOR YEAR 2016 FILED BY GENTICEL OF EUR 2.4 MILLION​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below